Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report

被引：0
|
作者：
Wang, W. [1 ]
Xu, C. [2 ]
Zhu, Y. [3 ]
Liao, X. [4 ]
Zhuang, W. [5 ]
Du, K. [3 ]
Chen, R. [6 ]
Chen, Y. [2 ]
Chen, G. [2 ]
Fang, M. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China
[3] Zhejiang Rongjun Hosp, Chest Dis Diag & Treatment Ctr, Jiaxing, Peoples R China
[4] Zhejiang Rongjun Hosp, Tumor Mol Lab, Jiaxing, Peoples R China
[5] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China
[6] Geneplus Beijing, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
crizotinib; Resistance; small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.1548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-018
引用
收藏
页码：S2244 / S2244
页数：1
相关论文
共 50 条
  • [31] Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report
    Madabhavi, Irappa
    Patel, Apurva
    Anand, Asha
    Panchal, Harsha
    Parikh, Sonia
    CLINICAL RESPIRATORY JOURNAL, 2018, 12 (02): : 806 - 810
  • [32] EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
    von Buttlar, Xinyu
    Reuss, Joshua E.
    V. Liu, Stephen
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [33] LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
    Yang, Yanlong
    Zheng, Hongbo
    Li, Zizhe
    Shi, Shuchen
    Zhong, Lang
    Gong, Longlong
    Lan, Bin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
    Rao, Chuangzhou
    Nie, Liangqin
    Wu, Xiaokang
    Miao, Xiaobo
    Chen, Ting
    Chen, Liuxi
    Zhang, Dongqing
    Lin, Quan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
    Qiu, Ye
    Li, Bixun
    Zhang, Yihong
    Guo, Xiaoyun
    Xiang, Chunzhi
    Wang, Congshui
    Lu, Yang
    Ren, Shuang
    Zhao, Juan
    MEDICINE, 2019, 98 (11)
  • [36] A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB
    Menefee, Michael E.
    D'Amico, Thomas A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1315 - S1316
  • [37] Cisplatin/crizotinib/pemetrexedLack of efficacy and acquired drug resistance: case report
    Reactions Weekly, 2022, 1894 (1) : 110 - 110
  • [38] Crizotinib/erlotinib/osimertinibAcquired drug resistance in pulmonary adenocarcinoma: case report
    Reactions Weekly, 2018, 1721 (1) : 96 - 96
  • [39] Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
    Chiang, Chi-Lu
    Yeh, Yi-Chen
    Chou, Teh-Ying
    Chiu, Chao-Hua
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (09) : 1439 - 1441
  • [40] Small Cell Transformation After Lorlatinib ALK Resistance - A Case Report with Clonal Evolution
    Xu, X.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S485 - S485
12345